A Simple Molecular Tool for the Assessment of Kidney Transplant Biopsies.
Journal
Clinical journal of the American Society of Nephrology : CJASN
ISSN: 1555-905X
Titre abrégé: Clin J Am Soc Nephrol
Pays: United States
ID NLM: 101271570
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
received:
26
08
2022
accepted:
17
01
2023
pmc-release:
01
04
2024
medline:
11
4
2023
pubmed:
2
2
2023
entrez:
1
2
2023
Statut:
ppublish
Résumé
The Banff Classification for Allograft Pathology recommendations for the diagnosis of kidney transplant rejection includes molecular assessment of the transplant biopsy. However, implementation of molecular tools in clinical practice is still limited, partly due to the required expertise and financial investment. The reverse transcriptase multiplex ligation-dependent probe amplification (RT-MLPA) assay is a simple, rapid, and inexpensive assay that permits simultaneous evaluation of a restricted gene panel using paraffin-embedded tissue blocks. The aim of this study was to develop and validate a RT-MLPA assay for diagnosis and classification of rejection. A retrospective cohort of 220 kidney transplant biopsies from two centers, which included 52 antibody-mediated rejection, 51 T-cell-mediated rejection, and 117 no-rejection controls, was assessed. A 17-gene panel was identified on the basis of relevant pathophysiological pathways. A support vector machine classifier was developed. A subset of 109 biopsies was also assessed using the Nanostring Banff Human Organ Transplant panel to compare the two assays. The support vector machine classifier train and test accuracy scores were 0.84 and 0.83, respectively. In the test cohort, the F1 score for antibody-mediated rejection, T-cell-mediated rejection, and control were 0.88, 0.86, and 0.69, respectively. Using receiver-operating characteristic curves, the area under the curve for class predictions was 0.96, 0.89, and 0.91, respectively, with a weighted average at 0.94. Classifiers' performances were highest for antibody-mediated rejection diagnosis with 94% correct predictions, compared with 88% correct predictions for control biopsies and 60% for T-cell-mediated rejection biopsies. Gene expression levels assessed by RT-MLPA and Nanostring were correlated: r = 0.68, P < 0.001. Equivalent gene expression profiles were obtained with both assays in 81% of the samples. The 17-gene panel RT-MLPA assay, developed here for formalin-fixed paraffin-embedded kidney transplant biopsies, classified kidney transplant rejection with an overall accurate prediction ratio of 0.83. This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_04_10_CJN10100822.mp3.
Sections du résumé
BACKGROUND
The Banff Classification for Allograft Pathology recommendations for the diagnosis of kidney transplant rejection includes molecular assessment of the transplant biopsy. However, implementation of molecular tools in clinical practice is still limited, partly due to the required expertise and financial investment. The reverse transcriptase multiplex ligation-dependent probe amplification (RT-MLPA) assay is a simple, rapid, and inexpensive assay that permits simultaneous evaluation of a restricted gene panel using paraffin-embedded tissue blocks. The aim of this study was to develop and validate a RT-MLPA assay for diagnosis and classification of rejection.
METHODS
A retrospective cohort of 220 kidney transplant biopsies from two centers, which included 52 antibody-mediated rejection, 51 T-cell-mediated rejection, and 117 no-rejection controls, was assessed. A 17-gene panel was identified on the basis of relevant pathophysiological pathways. A support vector machine classifier was developed. A subset of 109 biopsies was also assessed using the Nanostring Banff Human Organ Transplant panel to compare the two assays.
RESULTS
The support vector machine classifier train and test accuracy scores were 0.84 and 0.83, respectively. In the test cohort, the F1 score for antibody-mediated rejection, T-cell-mediated rejection, and control were 0.88, 0.86, and 0.69, respectively. Using receiver-operating characteristic curves, the area under the curve for class predictions was 0.96, 0.89, and 0.91, respectively, with a weighted average at 0.94. Classifiers' performances were highest for antibody-mediated rejection diagnosis with 94% correct predictions, compared with 88% correct predictions for control biopsies and 60% for T-cell-mediated rejection biopsies. Gene expression levels assessed by RT-MLPA and Nanostring were correlated: r = 0.68, P < 0.001. Equivalent gene expression profiles were obtained with both assays in 81% of the samples.
CONCLUSIONS
The 17-gene panel RT-MLPA assay, developed here for formalin-fixed paraffin-embedded kidney transplant biopsies, classified kidney transplant rejection with an overall accurate prediction ratio of 0.83.
PODCAST
This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_04_10_CJN10100822.mp3.
Identifiants
pubmed: 36723289
doi: 10.2215/CJN.0000000000000100
pii: 01277230-202304000-00014
pmc: PMC10103338
doi:
Substances chimiques
Antibodies
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
499-509Informations de copyright
Copyright © 2023 by the American Society of Nephrology.
Références
Sellarés J, de Freitas D, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12(2):388–399. doi: 10.1111/j.1600-6143.2011.03840.x
doi: 10.1111/j.1600-6143.2011.03840.x
Furness PN, Taub N; Convergence of European Renal Transplant Pathology Assessment Procedures (CERTPAP) Project. International variation in the interpretation of renal transplant biopsies: report of the CERTPAP Project1. Kidney Int. 2001;60(5):1998–2012. doi: 10.1046/j.1523-1755.2001.00030.x
doi: 10.1046/j.1523-1755.2001.00030.x
Halloran PF, Famulski KS, Reeve J. Molecular assessment of disease states in kidney transplant biopsy samples. Nat Rev Nephrol. 2016;12(9):534–548. doi: 10.1038/nrneph.2016.85
doi: 10.1038/nrneph.2016.85
Halloran PF, Venner JM, Madill-Thomsen KS, et al. Review: the transcripts associated with organ allograft rejection. Am J Transplant. 2018;18(4):785–795. doi: 10.1111/ajt.14600
doi: 10.1111/ajt.14600
Halloran PF, Reeve J, Akalin E, et al. Real time central assessment of kidney transplant indication biopsies by microarrays: the INTERCOMEX Study. Am J Transplant. 2017;17(11):2851–2862. doi: 10.1111/ajt.14329
doi: 10.1111/ajt.14329
Adam B, Afzali B, Dominy KM, et al. Multiplexed color-coded probe-based gene expression assessment for clinical molecular diagnostics in formalin-fixed paraffin-embedded human renal allograft tissue. Clin Transplant. 2016;30(3):295-305. doi: 10.1111/ctr.12689
doi: 10.1111/ctr.12689
Dominy KM, Willicombe M, Al Johani T, et al. Molecular assessment of C4d-positive renal transplant biopsies without evidence of rejection. Kidney Int Rep. 2019;4(1):148–158. doi: 10.1016/j.ekir.2018.09.005
doi: 10.1016/j.ekir.2018.09.005
Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell–mediated rejection, antibody‐mediated rejection, and prospects for integrative endpoints for next‐generation clinical trials. Am J Transplant. 2018;18(2):293–307. doi: 10.1111/ajt.14625
doi: 10.1111/ajt.14625
Roufosse C, Haas M, Loupy A, et al. The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant. 2021;21(5):1689–1690. doi: 10.1111/ajt.16419
doi: 10.1111/ajt.16419
Mengel M, Loupy A, Haas M, et al. Banff 2019 Meeting Report: molecular diagnostics in solid organ transplantation - consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation. Am J Transplant. 2020;20(9):2305–2317. doi: 10.1111/ajt.16059
doi: 10.1111/ajt.16059
Schinstock CA, Sapir-Pichhadze R, Naesens M, et al. Banff survey on antibody-mediated rejection clinical practices in kidney transplantation: diagnostic misinterpretation has potential therapeutic implications. Am J Transplant. 2019;19(1):123–131. doi: 10.1111/ajt.14979
doi: 10.1111/ajt.14979
Toulza F, Dominy K, Cook T, et al. Technical considerations when designing a gene expression panel for renal transplant diagnosis. Sci Rep. 2020;10(1):17909. doi: 10.1038/s41598-020-74794-3
doi: 10.1038/s41598-020-74794-3
Toulza F, Dominy K, Willicombe M, et al. Diagnostic application of transcripts associated with antibody-mediated rejection in kidney transplant biopsies. Nephrol Dial Transplant. 2022;37(8):1576–1584. doi: 10.1093/ndt/gfab231
doi: 10.1093/ndt/gfab231
Mareschal S, Ruminy P, Bagacean C, et al. Accurate classification of germinal center B-Cell–Like/Activated B-Cell–Like diffuse large B-cell lymphoma using a simple and rapid reverse transcriptase–multiplex ligation-dependent probe amplification assay: a CALYM Study. J Mol Diagn. 2015;17(3):273–283. doi: 10.1016/j.jmoldx.2015.01.007
doi: 10.1016/j.jmoldx.2015.01.007
Eldering E, Spek CA, Aberson HL, et al. Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. Nucleic Acids Res. 2003;31(23):e153. doi: 10.1093/nar/gng153
doi: 10.1093/nar/gng153
Dominy KM, Roufosse C, De Kort H, et al. Use of quantitative real time polymerase chain reaction to assess gene transcripts associated with antibody-mediated rejection of kidney transplants. Transplantation. 2015;99(9):1981–1988. doi: 10.1097/TP.0000000000000621 .
doi: 10.1097/TP.0000000000000621
Reeve J, Sellarés J, Mengel M, et al. Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. Am J Transplant. 2013;13(3):645–655. doi: 10.1111/ajt.12079
doi: 10.1111/ajt.12079
Halloran PF, Venner JM, Famulski KS. Comprehensive analysis of transcript changes associated with allograft rejection: combining universal and selective features. Am J Transplant. 2017;17(7):1754–1769. doi: 10.1111/ajt.14200
doi: 10.1111/ajt.14200
Aubert O, Loupy A, Hidalgo L, et al. Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients. J Am Soc Nephrol. 1912-19232017;28(6):1912–1923. doi: 10.1681/ASN.2016070797
doi: 10.1681/ASN.2016070797
Gologan S, Iacob R, Iancu D, et al. Inflammatory gene expression profiles in Crohn’s disease and ulcerative colitis: a comparative analysis using a reverse transcriptase multiplex ligation-dependent probe amplification protocol. J Crohns Colitis 2013;7(8):622–630. doi: 10.1016/j.crohns.2012.08.015
doi: 10.1016/j.crohns.2012.08.015
Bobée V, Ruminy P, Marchand V, et al. Determination of molecular subtypes of diffuse large B-cell lymphoma using a reverse transcriptase multiplex ligation-dependent probe amplification classifier: a CALYM Study. J Mol Diagn. 2017;19(6):892–904. doi: 10.1016/j.jmoldx.2017.07.007
doi: 10.1016/j.jmoldx.2017.07.007
Adam N, Coutance G, Drieux F, et al. RT-MLPA as a new tool for the molecular diagnosis of allograft rejection in formalin paraffin-embedded endomyocardial biopsies. J Heart Lung Transplant. 2018;37(4):S79. doi: 10.1016/j.healun.2018.01.179
doi: 10.1016/j.healun.2018.01.179
Drieux F, Ruminy P, Abdel-Sater A, et al. Defining the signatures of peripheral T-cell lymphoma, with a targeted 20-markers gene expression profiling assay (RT-MLPA). Haematologica. 2020;105(6):1582–1592. doi: 10.3324/haematol.2019.226647
doi: 10.3324/haematol.2019.226647
von Ahlfen S, Missel A, Bendrat K, Schlumpberger M. Determinants of RNA quality from FFPE samples. PLoS One. 2007;2(12):e1261. doi: 10.1371/journal.pone.0001261
doi: 10.1371/journal.pone.0001261
Madill-Thomsen K, Perkowska-Ptasińska A, Böhmig GA, et al. Discrepancy analysis comparing molecular and histology diagnoses in kidney transplant biopsies. Am J Transplant. 2020;20(5):1341–1350. doi: 10.1111/ajt.15752
doi: 10.1111/ajt.15752
Vaulet T, Divard G, Thaunat O, et al. Data-driven derivation and validation of novel phenotypes for acute kidney transplant rejection using semi-supervised clustering. J Am Soc Nephrol. 2021;32(5):1084–1096. doi: 10.1681/ASN.2020101418
doi: 10.1681/ASN.2020101418
Callemeyn J, Lamarthée B, Koenig A, Koshy P, Thaunat O, Naesens M. Allorecognition and the spectrum of kidney transplant rejection. Kidney Int. 2022;101(4):692–710. doi: 10.1016/j.kint.2021.11.029
doi: 10.1016/j.kint.2021.11.029
Adam BA, Kikic Z, Wagner S, et al. Intragraft gene expression in native kidney BK virus nephropathy versus T cell-mediated rejection: prospects for molecular diagnosis and risk prediction. Am J Transplant. 2020;20(12):3486–3501. doi: 10.1111/ajt.15980
doi: 10.1111/ajt.15980
Collins GS, Dhiman P, Andaur Navarro CL, et al. Protocol for development of a reporting guideline (TRIPOD-AI) and risk of bias tool (PROBAST-AI) for diagnostic and prognostic prediction model studies based on artificial intelligence. BMJ Open. 2021;11(7):e048008. doi: 10.1136/bmjopen-2020-048008
doi: 10.1136/bmjopen-2020-048008